Assessment of Treatment Response and Recurrence in Esophageal Carcinoma Based on Tumor Length and Standardized Uptake Value on Positron Emission Tomography-Computed Tomography

Annals of Thoracic Surgery

Volumn 86, Issue 4, 2008, Pages 1131-1138

  Roedl, Johannes B ^a   Harisinghani, Mukesh G ^a   Colen, Rivka R ^a   Fischman, Alan J ^a   Blake, Michael A ^a   Mathisen, Douglas J ^a   Mueller, Peter R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; LUTETIUM; LUTETIUM OXYORTHOSILICATE; SILICATE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; ESOPHAGUS CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 52049112795     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2008.05.019     Document Type: Article

References (29)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Berger A.C., Farma J., Scott W.J., et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23 (2005) 4330-4337
3. Urba S.G., Orringer M.B., Turrisi A., Iannettoni M., Forastiere A., and Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19 (2001) 305-313
4. Ancona E., Ruol A., Santi S., et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91 (2001) 2165-2174
5. DeYoung C.M., Suntharalingam M., Line B.R., et al. The ability of whole-body FDG18 PET imaging to predict pathologic response to induction chemoradiotherapy in locally advanced esophageal cancer: a prospective phase II trial. [Abstract]. Int J Radiat Oncol Biol Phys 57 Suppl 2 (2003) 165-166
6. Downey R.J., Akhurst T., Ilson D., et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of prospective trial. J Clin Oncol 21 (2003) 428-432
7. Ott K., Weber W., Lordick F., et al. Final results of a prospective trial: metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the esophagogastric junction (AEG). J Clin Oncol 24 (2006) 4692-4698
8. Kato H., Kuwano H., Nakajima M., et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184 (2002) 279-283
9. Song S.Y., Kim J.H., Ryu J.S., et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1053-1059
10. Brink I., Hentschel M., Bley T.A., et al. Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. Eur J Surg Oncol 30 (2004) 544-550
11. Nandurkar S., and Talley N.J. Barrett's esophagus: the long and the short of it. Am J Gastroenterol 94 (1999) 30-40
12. Sharma P. Recent advances in Barrett's esophagus: short-segment Barrett's esophagus and cardia intestinal metaplasia. Semin Gastrointest Dis 10 (1999) 93-102
13. Bhutani M.S., Barde C.J., Markert R.J., and Gopalswamy N. Length of esophageal cancer and degree of luminal stenosis during upper endoscopy predict T stage by endoscopic ultrasound. Endoscopy 34 (2002) 461-463
14. Eloubeidi M.A., Desmond R., Arguedas M.R., Reed C.E., and Wilcox C.M. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer 95 (2002) 1434-1443
15. Law S.Y.K., Fok M., and Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg 83 (1996) 107-111
16. Raoul J.L., Le Prise E., Meunier B., et al. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut 37 (1995) 174-176
17. Siewert J.R., and Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85 (1998) 1457-1459
18. Becker K., Mueller J.D., Schulmacher C., et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98 (2003) 1521-1530
19. Leong T., Everitt C., Yuen K., et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 78 (2006) 254-261
20. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8 (2007) 797-805
21. Siewert J.R., Lordick F., Ott K., et al. Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg 246 (2007) 624-628
22. Zasadny K.R., and Wahl R.L. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 189 (1993) 847-850
23. Choi J.Y., Jang H.J., Shim Y.M., et al. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 45 (2004) 1843-1850
24. Raoul J.L., Le Prise E., Meunier B., et al. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut 37 (1995) 174-176
25. Carlisle J.G., Quint L.E., Francis I.R., Orringer M.B., Smick J.F., and Gross B.H. Recurrent esophageal carcinoma: CT evaluation after esophagectomy. Radiology 189 (1993) 271-275
26. Esteves F.P., Schuster D.M., and Halkar R.K. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med 36 (2006) 169-181
27. Skehan S.J., Brown A.L., Thompson M., Young J.E., Coates G., and Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics 20 (2000) 713-723
28. Prabhakar H.B., Sahani D.V., Fischman A.J., Mueller P.R., and Blake M.A. Bowel hot spots at PET-CT. Radiographics 27 (2007) 145-159
29. Israel O., Mor M., Guralnik L., et al. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?. J Nucl Med 45 (2004) 2045-2051